Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The study is a randomized, double-blind, placebo-controlled study to evaluate the safety and
tolerability of LUM001. Efficacy will be assessed by evaluating the effect of LUM001 versus
placebo on the biochemical markers and pruritus associated with Alagille Syndrome.